Dingdang Health (09886) has released its interim results for the six months ending June 30, 2026, revealing a net loss attributable to shareholders of RMB 64.371 million, representing a 24.6% increase from the prior year period.

The company posted total revenue of RMB 2.409 billion, marking a modest 3.5% year-on-year growth. The loss per share stood at RMB 0.05 during the reporting period.

According to the official announcement, the company faced considerable operational headwinds driven by heightened industry competition during the reporting period. Despite these challenges, total revenue still achieved year-on-year growth, primarily attributed to improvements in overall operational efficiency, optimized product mix, and enhanced supply chain service capabilities.